Breaking News: Human BioSystems Continues Platelet Testing at Second Independent Laboratory.

PALO ALTO, Calif. -- Human BioSystems (OTCBB:HBSC), developer of preservation platforms for organs and other biomaterials, announces today that it plans to commence blood platelet testing at a second independent laboratory under a research agreement signed in June, 2005.

This agreement calls for the laboratory to assist the Company in testing its methods and protocols for extending the storage of blood platelets. The goal is to confirm in-vitro (test tube) results obtained by HBS in conjunction with another independent laboratory, and then to proceed to human infusion studies. "We decided to enlist a second laboratory to conduct the same tests in order to give us greater confidence in our results," said Dr. Winter, President of Human BioSystems. Testing is scheduled to start in January 2006.

The first independent laboratory contracted by HBS has recently completed the in-vitro test phase and is now preparing to proceed to human infusion studies, pending further internal and FDA approvals that may be required before starting the tests. "We are pleased with the in-vitro results from the first laboratory and are anxious to see the results of the infusion studies," noted Dr. Winter.

Blood platelets are the clotting component of blood and are collected from donors and infused into cancer patients that have undergone chemotherapy and/or radiation treatments. Such treatments inhibit the production of platelets for a period of time which can result in bleeding without regular platelet infusion.

"Currently, platelets have an FDA mandated 5 day shelf life. It is our goal to extend the shelf life by utilizing the proprietary HBS solution and process to preserve platelets at refrigerated temperatures for at least 7 or more days," said Dr. Winter.

"We believe that if our technology is successful and brought to market it would drastically reduce the outdating of platelets, allowing blood centers to significantly reduce their costs. We also believe that refrigeration will inhibit bacteria growth, resulting in a safer product," added Harry Masuda, CEO of Human BioSystems.

HBS is headquartered in Palo Alto, California with research facilities in Michigan.

Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.

Human BioSystems (OTC Bulletin Board:HBSC)